ADRB2 and Alzheimer disease: Retrospective analyses have suggested that individuals exposed to β2-AR agonists have a reduced risk of developing AD, with hazard ratios indicating a protective effect, while an increased risk was observed with patients receiving non selective β2 AR agonists.